Scholars@Duke publication: Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other

Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA

April 2, 2026

Published version (DOI) Publisher Link

<p>Supplementary Figure S1 shows ZN-c5 is a novel SERD that inhibits growth of ER + tumors in vitro and in vivo A. ERα degradation curve after ZN-c5 treatment and DC50 (concentration at 50% degradation) determination for Figure 1B top; B. Top: western blot analysis of ERα degradation at 24 hours after fulvestrant treatment in MCF-7 cells at indicated concentration; Bottom: ERα degradation curve and DC50 determination for fulvestrant; C. Tumor growth curve of MCF-7 xenograft model. Mice bearing MCF-7 tumor cells were dosed orally once a day for 26 days. D&E, body weight changes after ZN-c5 or fulvestrant treatment.</p>

Duke Scholars

Author Donald Patrick McDonnell Pharmacology & Cancer Biology

Author Suzanne E Wardell Pharmacology & Cancer Biology

Author Binita Chakraborty

Altmetric Attention Stats

Dimensions Citation Stats

DOI

10.1158/1535-7163.31923586

Publication Date

April 2, 2026

Citation

APA

Chicago

ICMJE

MLA

NLM

Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2026). Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. https://doi.org/10.1158/1535-7163.31923586

Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models,” April 2, 2026. https://doi.org/10.1158/1535-7163.31923586.

Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, et al. Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

Ma, Jianhui, et al. Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2 Apr. 2026. Crossref, doi:10.1158/1535-7163.31923586.

Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

DOI

10.1158/1535-7163.31923586

Publication Date

April 2, 2026